Survey Finds Migraine Patients Largely Unaware of Newly Available CGRP Medications
People living with migraine recently gained another significant tool to effectively manage their condition when the U.S. Food and Drug Administration approved the first treatment to target calcitonin-gene-related peptides (CGRP). However, only one-third of respondents of Migraine In America 2018, a national survey by Health Union, LLC of people impacted by the condition, are even aware of CGRP therapies.